TLDR
- OpenAI unveiled GPT-Rosalind on April 17, 2026, a new AI model built for drug discovery and biological research
- The model aims to cut into the 10–15 year U.S. drug approval timeline by accelerating early-stage research
- It is available to qualified users via ChatGPT, Codex, and the API, with a free plugin connecting to 50+ scientific tools
- Partners include Amgen, Moderna, Thermo Fisher Scientific, the Allen Institute, and Novo Nordisk
- Thermo Fisher Scientific holds a GF Score of 86/100, though insiders sold $8.2 million in shares over the past three months
OpenAI launched GPT-Rosalind on April 17, 2026, a new AI model designed to support research in biology, drug discovery, and translational medicine.
Introducing GPT-Rosalind, our frontier reasoning model built to support research across biology, drug discovery, and translational medicine. pic.twitter.com/PubLU0FkSv
— OpenAI (@OpenAI) April 16, 2026
The model is named after Rosalind Franklin, the scientist whose work helped reveal the structure of DNA.
Getting a new drug approved in the United States typically takes 10 to 15 years. OpenAI says GPT-Rosalind is built to speed up the earliest stages of that process.
The model is designed to help scientists work through large amounts of research literature, databases, and experimental data more quickly.
It supports tasks like literature review, hypothesis generation, experimental planning, and sequence-to-function interpretation.
GPT-Rosalind is available as a research preview through ChatGPT, Codex, and OpenAI’s API. Access is currently limited to qualified enterprise customers in the United States.
OpenAI also released a free Life Sciences research plugin for Codex. It connects to more than 50 scientific databases and tools.
How the Model Performs
On BixBench, a benchmark focused on real-world bioinformatics tasks, GPT-Rosalind scored 0.751, ahead of GPT-5.4 at 0.732 and Grok 4.2 at 0.698.
On LABBench2, the model outperformed GPT-5.4 on 6 out of 11 research tasks. Its strongest gain came in DNA cloning protocol design.
OpenAI also tested the model with Dyno Therapeutics using unpublished RNA sequences. The model ranked above the 95th percentile of human experts on a prediction task.
Key Industry Partners
OpenAI is working with Amgen, Moderna, Novo Nordisk, Thermo Fisher Scientific, NVIDIA, Oracle Health and Life Sciences, the Allen Institute, Benchling, and UCSF School of Pharmacy.
Amgen’s Senior Vice President of AI and Data said the collaboration with OpenAI allows them to apply advanced tools in new ways to speed up how medicines reach patients.
Thermo Fisher Scientific, one of the named partners, has a market cap of around $191.76 billion. The company provides scientific instruments, lab equipment, and life science reagents.
Thermo Fisher carries a GF Score of 86 out of 100, with a Profitability Rank of 8/10 and a Growth Rank of 7/10.
Over the past three months, insiders at Thermo Fisher sold $8.2 million worth of shares, with no recorded insider buying in the same period.
The model is backed by Microsoft, which has a longstanding investment relationship with OpenAI.
🚨 Our April Stock Picks Are Live!
A new month means new opportunities. Our analysts have just released their top stock picks for April, highlighting companies with strong momentum that rank highly on our KO Score algorithm. We’re also now sharing trade ideas for both long-term and short-term investors, giving you more ways to spot potential opportunities in the market.
Sign up to Knockout Stocks today and get 50% off to unlock the full list and see which stocks made the cut.
Use coupon code Special50 for your exclusive discount!
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
